ML133 HCl: Selective Kir2.1 Channel Blocker for PASMC Research

Executive Summary: ML133 HCl is a potent and selective inhibitor of the Kir2.1 potassium channel, demonstrating an IC₅₀ of 1.8 μM at pH 7.4 and 290 nM at pH 8.5 [ApexBio]. It shows no inhibition of Kir1.1 and only weak effects on Kir4.1 and Kir7.1, enabling high specificity in ion channel research [Cao et al., 2022]. ML133 HCl is widely used for studying pulmonary artery smooth muscle cell (PASMC) proliferation and migration—key processes in cardiovascular disease models [cpi-613.com]. Its solubility profile (≥15.7 mg/mL in DMSO, ≥2.52 mg/mL in ethanol) and recommended storage at -20°C support robust experimental workflows [ApexBio]. Inhibition of Kir2.1 by ML133 HCl downregulates the TGF-β1/SMAD2/3 pathway and markers of proliferation, providing a mechanistic link to reduced PASMC proliferation [Cao et al., 2022].

Biological Rationale

Kir2.1 is a classical inwardly rectifying potassium channel encoded by the KCNJ2 gene. It is expressed in vascular smooth muscle, including pulmonary artery smooth muscle cells (PASMCs) [Cao et al., 2022]. Kir2.1 channels regulate membrane potential and potassium ion (K⁺) homeostasis. Abnormal Kir2.1 function is implicated in pulmonary hypertension (PH), characterized by increased pulmonary arterial pressure and vascular remodeling [Cao et al., 2022]. PASMC proliferation and migration are hallmarks of PH and contribute to vascular remodeling. Modulating Kir2.1 activity directly influences these cellular processes. Identifying selective inhibitors like ML133 HCl enables precise mechanistic dissection of Kir2.1’s role in cardiovascular disease models.

Mechanism of Action of ML133 HCl

ML133 HCl is the hydrochloride salt of 1-(4-methoxyphenyl)-N-(naphthalen-1-ylmethyl)methanamine. Its molecular weight is 313.82 g/mol, and its chemical formula is C₁₉H₁₉NO·HCl [ApexBio]. ML133 HCl acts as a selective inhibitor of the Kir2.1 channel. At pH 7.4, its IC₅₀ is 1.8 μM, while at pH 8.5, the IC₅₀ decreases to 290 nM, indicating increased potency at alkaline pH [ApexBio]. ML133 HCl does not inhibit Kir1.1 and only weakly inhibits Kir4.1 and Kir7.1, ensuring selectivity in experimental systems. The compound blocks Kir2.1-mediated potassium ion transport, leading to alterations in membrane potential. In PASMCs, this blockade inhibits proliferation and migration, as demonstrated in both in vitro and in vivo experimental models [Cao et al., 2022]. Importantly, ML133 HCl downregulates the TGF-β1/SMAD2/3 signaling pathway and decreases expression of proliferation markers such as OPN and PCNA.

Evidence & Benchmarks

• ML133 HCl inhibits Kir2.1 channels with an IC₅₀ of 1.8 μM at pH 7.4 and 290 nM at pH 8.5 (Product data sheet).
• It shows no inhibition of Kir1.1 and only weak activity against Kir4.1 and Kir7.1 channels, demonstrating high selectivity (Product data sheet).
• In vivo, Kir2.1 expression is upregulated in PASMCs during pulmonary hypertension; ML133 HCl reverses this effect and reduces PASMC proliferation and migration (Cao et al., 2022).
• ML133 HCl treatment inhibits the TGF-β1/SMAD2/3 signaling pathway and reduces expression of OPN and PCNA in PDGF-BB-stimulated PASMCs (Cao et al., 2022).
• ML133 HCl is insoluble in water but dissolves in DMSO (≥15.7 mg/mL) and ethanol (≥2.52 mg/mL) with gentle warming and ultrasonic treatment (Product data sheet).
• For extended mechanistic context, see "ML133 HCl: Unveiling New Dimensions in Kir2.1 Channel Inhibition". This article updates the mechanistic insights with recent experimental data.
• For translational applications, compare with "Precision Potassium Channel Inhibition". This article provides strategic guidance, while the current review details empirical benchmarks and workflow integration.

Applications, Limits & Misconceptions

ML133 HCl is widely used in research on pulmonary artery smooth muscle cell (PASMC) proliferation, vascular remodeling, and cardiovascular disease models. Its high selectivity makes it suitable for dissecting the specific role of Kir2.1 channels in potassium ion transport and vascular smooth muscle cell dynamics. The compound is valuable in studies aiming to understand mechanisms of pulmonary hypertension and to screen for new targeted therapeutics. However, ML133 HCl is not a pan-Kir channel inhibitor and should not be used to draw conclusions about other Kir family channels. Additionally, its stability in solution is limited, requiring fresh preparation for each experiment.

Common Pitfalls or Misconceptions

• Using ML133 HCl as a general potassium channel blocker—its action is specific to Kir2.1, with minimal effects on Kir1.1, Kir4.1, or Kir7.1.
• Assuming water solubility—ML133 HCl is insoluble in water and must be dissolved in DMSO or ethanol with gentle warming and ultrasonic treatment.
• Long-term storage of ML133 HCl in solution—compound stability is compromised; only solid-state storage at -20°C is recommended.
• Extrapolating effects to other cell types or signaling pathways without validation—ML133 HCl’s characterized effects are specific to Kir2.1 in PASMCs and related systems.
• Neglecting pH dependence—the compound’s potency increases under alkaline conditions (lower IC₅₀ at pH 8.5).

Workflow Integration & Parameters

ML133 HCl (B2199 kit) is supplied as a solid. For experimental use, dissolve in DMSO at concentrations ≥15.7 mg/mL or in ethanol at ≥2.52 mg/mL. Use gentle warming and ultrasonic treatment to enhance solubility. Prepare fresh solutions for each assay due to limited stability in solution. Store solid stock at -20°C to maintain long-term stability. Typical experimental protocols involve pre-treatment of PASMCs with ML133 HCl for 24 hours, followed by stimulation (e.g., with PDGF-BB) to assess effects on proliferation and migration [Cao et al., 2022]. For advanced integration and experimental strategies, see "Translational Impact of Selective Kir2.1 Channel Inhibition", which this article extends by providing detailed workflow parameters and empirical dosing guidance.

Conclusion & Outlook

ML133 HCl is a reference tool for selective inhibition of the Kir2.1 potassium channel in cardiovascular and pulmonary research. Its unique selectivity and well-defined solubility parameters make it an optimal choice for dissecting the mechanistic role of Kir2.1 in PASMC proliferation and vascular remodeling. Current evidence supports its utility in both basic and translational settings. Ongoing research may further clarify its therapeutic potential and inform next-generation targeted potassium channel modulators.